In Europe, the emergence of the severe acute respiratory syndrome (SARS) coronavirus, the H5N1 influenza virus, and the threat of bioterrorism have, according to Caroline Brown (WHO Regional Office for Europe, Copenhagen, Denmark), "now combined to stimulate intensive preparedness activities in every one of Europe\'s 53 states".

Newly emerging viral infections (SARS), re-emerging ones (West Nile virus), and infectious disease agents spread deliberately by bioterrorism (anthrax) are seen as important threats that have the potential to severely disrupt public health systems worldwide. "SARS has taught us that a global health crisis can be more effectively countered through an international effort of communication and cooperation rather than local initiatives or uncoordinated actions", stressed Giuseppe Ippolito (National Institute of Infectious Diseases, Rome, Italy), who is involved in the European Network of Biosafety Level 4 Laboratories ([Euronet-P4](http://www.euronetp4.eu/)). [Many such laboratory networks](http://www.who.int/collaboratingcentres/networks/networksdetails/en/index7.html) have recently been established and enhanced by the European Union and WHO. "Europe is better prepared than ever for a sudden outbreak caused by a previously unknown pathogenic agent", commented Franz Allerberger (Austrian Agency for Health and Food Safety, Vienna, Austria).

Euronet-P4 was established in 2005 with the aim of improving laboratory identification of dangerous pathogens, sharing samples, reagents, and protocols, standardising biosafety and biosecurity procedures, and promoting communication and training. It involves active collaboration between seven internationally recognised biosafety level 4 (BSL4) laboratories in the European Union (EU), in five countries (UK, Germany, Sweden, Italy, France), with additional facilities under construction or being planned. These specialist centres all have state-of-the-art technical facilities and staff trained in the most stringent biocontainment procedures that enable the safe study of risk group 4 agents such as Ebola virus and Marburg virus. "This classification denotes the most potentially lethal pathogens known, some of which are regarded as likely bioweapons", explained Ippolito.

During the first 2 years, Euronet-P4 concentrated on the assessment of diagnostic capability and biosafety features of existing laboratories. The results highlighted the need to standardise virus isolation techniques to allow safe identification of filoviruses, arenaviruses, orthopoxviruses, and Crimean-Congo haemorrhagic fever virus. "There is also a requirement to improve serological tests and to obtain human serum samples to use as positive controls, work that will continue over the next 3 years because of additional funding", added Ippolito.

Johan Giesecke, Chief Scientific Officer of the European Centre for Disease Prevention and Control (ECDC), agrees, and points out that standardisation is now needed for common as well as rare diseases. "Tests for many common pathogens are still not comparable between different laboratories. ECDC has arranged expert group meetings to discuss specific tests and this effort needs to be sustained: [Enter-net](http://ec.europa.eu/health/ph_threats/com/networks/network_enternet_en.htm), an EU network project to harmonise salmonella testing methods, took 15 years to achieve its objectives", he explained. But, the effort paid off: outbreak recognition and the efficiency of investigations in the EU has improved, and national surveillance has been strengthened.

Euronet-P4 is now continuing as the ENP4-Lab project, which will run until the end of 2010. The venture has already gained an additional participant, the INSERM Institute in Lyon, France, which will help address the problems in standardising diagnostic procedures and increasing biosafety across the network. For rarer tropical diseases, Ippolito suggests that "collaboration with laboratories outside Europe should be increased in the future so that sera obtained from endemic regions can be used in validation studies". Specific plans have been made to establish successful collaborations with research institutions located close to where frequent outbreaks of rare tropical diseases occur, such as the BSL4 laboratory in Gabon. The EU also needs to organise external quality control trials as a prerequisite to improve its diagnostic capacity, commented Allerberger. "Cooperation between public health institutes will allow Europe to cope with the task of diagnostic validation and I feel direct communication between institutes is preferable to collaborations set up via political channels, because these are rarely effective", he added.
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The network is also investigating the feasibility of a mobile laboratory that can handle highly infectious pathogens safely, Ippolito told *TLID*. This would increase European preparedness and could provide invaluable support during investigations in outbreak-prone countries beyond Europe. "All of these activities are part of a wider strategy of collaboration among European countries and international organisations such as WHO and the laboratory network of the Global Health Security Action Group to build our collective capacity to respond effectively to global infectious disease emergencies", concluded Ippolito.
